These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 19436050

  • 1. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.
    Blood; 2009 Jul 30; 114(5):1046-52. PubMed ID: 19436050
    [Abstract] [Full Text] [Related]

  • 2. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
    Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T.
    Int J Oncol; 2014 Apr 30; 44(4):1171-6. PubMed ID: 24481412
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
    Lee KH, Jeong J, Yoo CG.
    J Biol Chem; 2013 Nov 08; 288(45):32777-32786. PubMed ID: 24085292
    [Abstract] [Full Text] [Related]

  • 6. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan 08; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
    Salem K, Brown CO, Schibler J, Goel A.
    Exp Hematol; 2013 Feb 08; 41(2):209-18. PubMed ID: 23063726
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
    Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.
    Mol Cancer Res; 2011 Feb 08; 9(2):183-94. PubMed ID: 21224428
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM, Tepper JE, Baldwin AS, Liu R, Adams J, Elliott P, Cusack JC.
    Int J Radiat Oncol Biol Phys; 2001 May 01; 50(1):183-93. PubMed ID: 11316563
    [Abstract] [Full Text] [Related]

  • 11. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ.
    Oncogene; 2002 Sep 19; 21(42):6510-9. PubMed ID: 12226754
    [Abstract] [Full Text] [Related]

  • 12. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF, Yu LJ, Meng YF, Lv HY, Meng J, Song XN, Zhang JQ.
    Leuk Lymphoma; 2013 Mar 19; 54(3):607-18. PubMed ID: 22889356
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.
    Int J Oncol; 2013 Mar 19; 42(3):935-44. PubMed ID: 23340716
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct 19; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
    Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY.
    J Biol Chem; 2010 May 21; 285(21):16096-104. PubMed ID: 20335171
    [Abstract] [Full Text] [Related]

  • 19. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
    Amschler K, Schön MP, Pletz N, Wallbrecht K, Erpenbeck L, Schön M.
    J Invest Dermatol; 2010 Apr 21; 130(4):1073-86. PubMed ID: 19940859
    [Abstract] [Full Text] [Related]

  • 20. Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
    Jia L, Gopinathan G, Sukumar JT, Gribben JG.
    PLoS One; 2012 Apr 21; 7(2):e32584. PubMed ID: 22393418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.